富祥药业2024净利降36%，董事长包建华夫妇合计领薪187万

Financial Performance - In 2024, the company's operating revenue was 1.18 billion yuan, a decrease of 26.83% compared to 2023 [1] - The net profit attributable to shareholders was -272.10 million yuan, down 35.51% year-on-year [1] - The net profit after deducting non-recurring gains and losses was -304.53 million yuan, a decline of 54.12% from the previous year [1] - The basic earnings per share were -0.51 yuan, reflecting a 37.84% decrease compared to the previous year [1] Profitability Metrics - The gross margin for 2024 was 9.67%, a decrease of 0.96% year-on-year [2] - The net profit margin was -23.81%, down 9.94% from the previous year [2] Expense Management - Total operating expenses for 2024 were 257 million yuan, a reduction of 62.21 million yuan compared to the previous year [2] - The expense ratio increased to 21.80%, up 1.98% year-on-year [2] - Sales expenses decreased by 52.50%, management expenses decreased by 13.42%, and R&D expenses decreased by 23.39% [2] Employee Statistics - The total number of employees at the end of 2024 was 1,774, a decrease of 189 employees or 9.63% from the previous year [3][4] Executive Compensation - Total compensation for directors, supervisors, and senior management in 2024 amounted to 8.24 million yuan [6] - The highest-paid individual was the chairman and general manager, Bao Jianhua, who received 1.25 million yuan [6][7]